(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Morton's Neuroma
National Institutes of Health Clinical Center (CC)Small moleculePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Morton's Neuroma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cntx-4975 Centrexion Therapeutics | Phase 2 | B |
Lopain National Institutes of Health Clinical Center (CC) | Phase 1 | CC |
Capsaicin Centrexion Therapeutics | Phase 1 | CC |
Xylocaine AstraZeneca | Early Phase 1 | CC |
LIDOCAINE Brown University | N/A | D |
92.3% TO NMT 93.8% ETHANOL BY WEIGHT IN WATER Brown University | N/A | D |
Same molecule, other indications
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →